Model Driven Optimization of Drug Delivery for Spinal Cord Injury

2021 ◽  
Author(s):  
Neil Mittal
Keyword(s):  
Drug Delivery ◽  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Model Driven ◽  
Cord Injury

Multiple drug delivery hydrogel system for spinal cord injury repair strategies

2012 ◽  
Vol 159 (2) ◽  
pp. 271-280 ◽  
Author(s):  
Giuseppe Perale ◽  
Filippo Rossi ◽  
Marco Santoro ◽  
Marco Peviani ◽  
Simonetta Papa ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Multiple Drug ◽  
Injury Repair ◽  
Cord Injury ◽  
Multiple Drug Delivery ◽  
Hydrogel System

scholarly journals Synthesis and Characterization of a Silica-Based Drug Delivery System for Spinal Cord Injury Therapy

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Guodong Sun ◽  
Shenghui Zeng ◽  
Xu Liu ◽  
Haishan Shi ◽  
Renwen Zhang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Mesoporous Silica ◽  
Drug Delivery System ◽  
Delivery System ◽  
Central Component ◽  
High Dose ◽  
Interleukin 17 ◽  
Cord Injury

Abstract Acute inflammation is a central component in the progression of spinal cord injury (SCI). Anti-inflammatory drugs used in the clinic are often administered systemically at high doses, which can paradoxically increase inflammation and result in drug toxicity. A cluster-like mesoporous silica/arctigenin/CAQK composite (MSN-FC@ARC-G) drug delivery system was designed to avoid systemic side effects of high-dose therapy by enabling site-specific drug delivery to the spinal cord. In this nanosystem, mesoporous silica was modified with the FITC fluorescent molecule and CAQK peptides that target brain injury and SCI sites. The size of the nanocarrier was kept at approximately 100 nm to enable penetration of the blood–brain barrier. Arctigenin, a Chinese herbal medicine, was loaded into the nanosystem to reduce inflammation. The in vivo results showed that MSN-FC@ARC-G could attenuate inflammation at the injury site. Behavior and morphology experiments suggested that MSN-FC@ARC-G could diminish local microenvironment damage, especially reducing the expression of interleukin-17 (IL-17) and IL-17-related inflammatory factors, inhibiting the activation of astrocytes, thus protecting neurons and accelerating the recovery of SCI. Our study demonstrated that this novel, silica-based drug delivery system has promising potential for clinical application in SCI therapy.

scholarly journals Drug delivery, cell-based therapies, and tissue engineering approaches for spinal cord injury

2015 ◽  
Vol 219 ◽  
pp. 141-154 ◽  
Author(s):  
Shushi Kabu ◽  
Yue Gao ◽  
Brian K. Kwon ◽  
Vinod Labhasetwar
Keyword(s):  
Drug Delivery ◽  
Spinal Cord ◽  
Tissue Engineering ◽  
Spinal Cord Injury ◽  
Cord Injury

Nanovector-mediated drug delivery for spinal cord injury treatment

2014 ◽  
Vol 6 (5) ◽  
pp. 506-515 ◽  
Author(s):  
Ilaria Caron ◽  
Simonetta Papa ◽  
Filippo Rossi ◽  
Gianluigi Forloni ◽  
Pietro Veglianese
Keyword(s):  
Drug Delivery ◽  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Cord Injury ◽  
Injury Treatment
Sign in / Sign up

Export Citation Format

Share Document